Hospital del Mar / Hospital del Mar Research Institute
Barcelona's seaside university hospital, whose research institute under Joaquín Arribas leads HER2 biology and CAR-T against breast cancer.
Hospital del Mar and the Hospital del Mar Research Institute (formerly IMIM) form a cancer programme with Universitat Pompeu Fabra and the Universitat Autònoma de Barcelona. Joaquín Arribas, director of the institute, characterised the truncated p95HER2 receptor and developed CAR-T and T-cell engager approaches against it, and Joan Albanell's medical oncology group is a leading breast cancer trialist within the SOLTI network. The hospital runs a comprehensive cancer service including radiotherapy, hepatobiliary surgery and haematology, an early-phase unit, and population cancer epidemiology through its public health research groups.
- HER2 biology and p95HER2 CAR-T
- Breast cancer trials (SOLTI)
- Cancer epidemiology
- Early-phase trials
Pages like this
not linked directly; found by shared links- InstitutionInstituto Alexander Fleming
Shares Trastuzumab, HER2, HER2-positive breast cancer, HR-positive / HER2-negative breast cancer.
- InstitutionIstituto Oncologico Veneto IRCCS
Shares Trastuzumab, Monoclonal antibodies, HER2-positive breast cancer, HR-positive / HER2-negative breast cancer.
- InstitutionGeorgetown Lombardi Comprehensive Cancer Center
Shares Trastuzumab, Monoclonal antibodies, HER2, HER2-positive breast cancer.
- InstitutionIstituto di Candiolo IRCCS – FPO
Shares Trastuzumab, Monoclonal antibodies, HER2, HER2-positive breast cancer.
- PersonBarbara Bradfield
Shares Trastuzumab, Monoclonal antibodies, HER2, HER2-positive breast cancer.
- IdeaWHO prequalification plus pooled demand to push biosimilar prices below 10% of the originator
Shares Trastuzumab, Monoclonal antibodies, HER2-positive breast cancer.
- InstitutionSOLTI Cancer Research Group
Shares Vall d'Hebron University Hospital / VHIO, Trastuzumab, HER2-positive breast cancer, HR-positive / HER2-negative breast cancer.
- InstitutionIRCCS Ospedale San Raffaele
Shares Trastuzumab, HER2, HER2-positive breast cancer, CAR-T cell therapy.